Swedbank lessened its stake in shares of CVS Health Corp (NYSE:CVS) by 54.5% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 943,346 shares of the pharmacy operator’s stock after selling 1,130,232 shares during the period. Swedbank’s holdings in CVS Health were worth $74,260,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Camarda Financial Advisors LLC bought a new stake in shares of CVS Health during the second quarter valued at approximately $102,000. Quantbot Technologies LP bought a new stake in shares of CVS Health during the first quarter valued at approximately $103,000. Kiley Juergens Wealth Management LLC bought a new stake in shares of CVS Health during the second quarter valued at approximately $103,000. Legacy Advisors LLC raised its stake in shares of CVS Health by 7,100.0% during the second quarter. Legacy Advisors LLC now owns 1,800 shares of the pharmacy operator’s stock valued at $116,000 after acquiring an additional 1,775 shares in the last quarter. Finally, Squar Milner Financial Services LLC bought a new stake in shares of CVS Health during the second quarter valued at approximately $122,000. 82.75% of the stock is owned by hedge funds and other institutional investors.

Shares of CVS stock opened at $74.58 on Friday. The company has a market cap of $80.14 billion, a P/E ratio of 12.64, a price-to-earnings-growth ratio of 1.05 and a beta of 1.02. The company has a debt-to-equity ratio of 1.73, a quick ratio of 1.87 and a current ratio of 2.34. CVS Health Corp has a 52-week low of $60.14 and a 52-week high of $83.88.

CVS Health (NYSE:CVS) last issued its quarterly earnings data on Wednesday, August 8th. The pharmacy operator reported $1.69 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.61 by $0.08. CVS Health had a net margin of 1.61% and a return on equity of 18.25%. The company had revenue of $46.71 billion for the quarter, compared to analyst estimates of $46.34 billion. During the same period last year, the company posted $1.33 earnings per share. CVS Health’s revenue was up 2.2% compared to the same quarter last year. Sell-side analysts anticipate that CVS Health Corp will post 7.05 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Thursday, November 1st. Shareholders of record on Wednesday, October 24th will be issued a $0.50 dividend. This represents a $2.00 annualized dividend and a yield of 2.68%. The ex-dividend date is Tuesday, October 23rd. CVS Health’s dividend payout ratio is currently 33.90%.

In other CVS Health news, EVP Lisa Bisaccia sold 21,534 shares of CVS Health stock in a transaction on Monday, October 1st. The shares were sold at an average price of $80.00, for a total value of $1,722,720.00. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, EVP Kevin Hourican sold 8,564 shares of CVS Health stock in a transaction on Monday, August 27th. The stock was sold at an average price of $75.00, for a total transaction of $642,300.00. Following the completion of the transaction, the executive vice president now directly owns 12,135 shares in the company, valued at $910,125. The disclosure for this sale can be found here. Insiders sold 43,409 shares of company stock worth $3,392,097 over the last ninety days. Corporate insiders own 0.53% of the company’s stock.

CVS has been the subject of several research analyst reports. Bank of America lifted their price target on shares of CVS Health from $86.00 to $90.00 and gave the company a “buy” rating in a research note on Monday, September 17th. Royal Bank of Canada lifted their price objective on shares of CVS Health to $101.00 and gave the company an “outperform” rating in a report on Tuesday, September 18th. ValuEngine raised shares of CVS Health from a “strong sell” rating to a “sell” rating in a report on Tuesday, August 28th. Citigroup reissued a “buy” rating and set a $81.00 price objective on shares of CVS Health in a report on Monday, July 9th. Finally, Morgan Stanley cut their price objective on shares of CVS Health from $88.00 to $80.00 and set an “overweight” rating on the stock in a report on Tuesday, July 3rd. One investment analyst has rated the stock with a sell rating, five have issued a hold rating, ten have issued a buy rating and two have issued a strong buy rating to the stock. CVS Health has an average rating of “Buy” and an average price target of $86.31.

About CVS Health

CVS Health Corporation, together with its subsidiaries, provides integrated pharmacy health care services. It operates through Pharmacy Services and Retail/LTC segments. The Pharmacy Services segment offers pharmacy benefit management solutions, such as plan design and administration, formulary management, Medicare Part D services, mail order, specialty pharmacy and infusion services, retail pharmacy network management services, prescription management systems, clinical services, disease management programs, and medical pharmacy management services.

Read More: Book Value Per Share in Stock Trading

Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Corp (NYSE:CVS).

Institutional Ownership by Quarter for CVS Health (NYSE:CVS)

Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.